

Hollister Biosciences Inc.

Management's Discussion & Analysis

For the three and six months ended June 30, 2021 and 2020

Expressed in United States Dollars

Hollister Biosciences Inc.

For the three and six months ended June 30, 2021 and 2020

Management's Discussion & Analysis

Expressed in United States Dollars

This Management's Discussion & Analysis ("MD&A") of the financial condition and results of operations of Hollister Biosciences Inc. ("Hollister" or the "Company") should be read in conjunction with the Company's unaudited condensed interim consolidated financial statements "interim financial statements" for the three and six months ended June 30, 2021 and 2020, and the accompanying notes therein. This MD&A is dated August 25, 2021, which is the date that the Board of Directors of the Company (the "Board") approved the disclosure contained in this MD&A.

The results for the periods presented are not necessarily indicative of the results that may be expected for any future period. Except as otherwise indicated, all financial data in this MD&A has been prepared in accordance with International Financial Reporting Standards ("IFRS") issued by the International Accounting Standards Board ("IASB") and interpretations of the International Financial Reporting Interpretations Committee ("IFRIC"). The first, second, third and fourth quarters of the Company's fiscal years are referred to as "Q1", "Q2", "Q3" and "Q4", respectively. Periods for the six months ended June 30, 2021 and 2020 are referred to as "YTD 2021" and "YTD 2020", respectively.

All dollar amounts in this MD&A are expressed in United States Dollars except where otherwise indicated.

FORWARD-LOOKING STATEMENTS

This MD&A contains certain forward-looking information and forward-looking statements, as defined in applicable securities laws (collectively referred to herein as "forward-looking statements"). These statements relate to future events or the Company's future performance. All statements other than statements of historical fact are forward-looking statements. Often, but not always, forward-looking statements can be identified by the use of words such as "plans", "expects", "is expected", "budget", "scheduled", "estimates", "continues", "forecasts", "projects", "predicts", "intends", "anticipates" or "believes", or variations of, or the negatives of, such words and phrases, or state that certain actions, events or results "may", "could", "would", "should", "might" or "will" be taken, occur or be achieved. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to differ materially from those anticipated in such forward-looking statements. The forward-looking statements in this MD&A speak only as of the date of this MD&A or as of the date specified in such statement.

Inherent in forward-looking statements are risks, uncertainties and other factors beyond the Company's ability to predict or control. Please also refer to those risk factors in the "Risk Factors" and "Additional Risk Disclosure for Issuers with U.S. Cannabis Operations" section below. Actual results and developments are likely to differ, and may differ materially from those expressed or implied by the forward-looking statements contained in this MD&A.

Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results, performance or achievements to be materially different from any of its anticipated results, performance or achievements expressed or implied by forward-looking statements. All forward-looking statements herein are qualified by this cautionary statement. Accordingly, readers should not place undue reliance on forward-looking statements.

The Company undertakes no obligation to update publicly or otherwise revise any forward-looking statements whether as a result of new information or future events or otherwise, except as may be required by law. If the Company does update one or more forward-looking statements, no inference should be drawn that it will make additional updates with respect to those or other forward-looking statements, unless required by law.

USE OF NON-IFRS FINANCIAL MEASURES

This MD&A includes certain non-IFRS financial measures. Reconciliations of these non-IFRS financial measures to the most directly comparable financial measure calculated and presented in accordance with IFRS are included below. This information should be considered as supplemental in nature and not as a substitute for, or superior to, any measure of performance prepared in accordance with IFRS. Our management uses adjusted EBITDA to evaluate our operating performance and trends and make planning decisions. Our management believes adjusted EBITDA helps identify underlying trends in our business that could otherwise be masked by the effect of the items that we exclude. Accordingly, we believe that adjusted EBITDA provides useful information to investors and others in understanding and evaluating our operating results, enhancing the overall understanding of our past performance and future prospects, and allowing for greater transparency with respect to key financial metrics used by our management in its financial and operational decision-making.

Hollister Biosciences Inc.

For the three and six months ended June 30, 2021 and 2020

Management's Discussion & Analysis

Expressed in United States Dollars

CORPORATE OVERVIEW

Hollister Biosciences Inc. was incorporated on April 17, 2019 under the laws of the Province of British Columbia, Canada. On August 29, 2019, the Company changed its name from 1205600 B.C. Ltd to Hollister Biosciences Inc. (collectively herein referred to as the "Company", "Hollister"). The Company's registered and records office is located at 2100 Scotia Plaza, 40 King Street West, Toronto, Ontario, M5H 3C2, Canada. The Company was incorporated for the sole purpose of completing financings in anticipation of completing the acquisition of Weldon Manor, LLC, ("Weldon") and concurrently applying for a listing on the Canadian Securities Exchange (the "CSE") as described below. Weldon is a private licensed manufacturer and distributor of cannabis pre-roll and extract products in the State of California. On March 24, 2020, the Company acquired a 100% interest in Labtronix, Inc. doing business as Venom Extracts ("Venom Extracts") which is a leading Arizona cannabis extract brand and one of the state's largest producers of award-winning medical cannabis distillate and related products. On April 30, 2020, the Company acquired a 100% interest in AlphaMind Brands Inc. a growth stage company that is developing a portfolio of certified legal mushroom based natural health products. The Company is listed on the CSE under the symbol "HOLL".

The Company operates as a licensed manufacturer and distributor of recreational cannabis and cannabis products, and distributes its products through an arrangement with a cannabis distributor to licensed cannabis vendors in California and Arizona. The Company commenced revenue generating activity during the year ended December 31, 2018. Continuance of operations is dependent upon maintaining the necessary licensing under California state law. The Company does not currently expect to need to obtain financing to perform operating activities and meet ongoing obligations, however this may be required if there are significant changes in the future economic or regulatory environment.

Although the Corporation's activities are compliant with all applicable Arizona and California state and local laws, strict compliance with state and local laws with respect to cannabis may neither absolve the Corporation of liability under United States federal law nor provide a defense to federal criminal charges that may be brought against the Corporation. The Supremacy Clause of the United States Constitution establishes that the United States Constitution and federal laws made pursuant to it are paramount and, in case of conflict between federal and State law, the federal law shall apply.

The Company is classified as having a "direct" involvement in the United States cannabis industry and is in compliance with applicable United States state law and related licensing requirements and the regulatory framework enacted by the State of Arizona and State of California. The Company is not subject to any citations or notices of violation with applicable licensing requirements and the regulatory frameworks which may have an impact on its licenses, business activities or operations. The Company uses reasonable commercial efforts to ensure that its business is in compliance with applicable licensing requirements and the regulatory frameworks enacted by Nevada, through the advice of its General Counsel, who monitors and reviews its business practices and changes to United States Federal enforcement priorities.

The Company's General Counsel works with external legal advisors in Arizona and California, to ensure that the Company is in on-going compliance with applicable state laws.

CORPORATE OUTLOOK

Corporate Outlook

In March of 2017, the Company commenced construction of a large legal cannabis facility. The Company has a 37,061 sq. ft. facility in Hollister, California (the "Hollister Facility") that is being developed in phases. The Company has leased a total of 17,600 sq. ft. of this facility to other cannabis companies to reduce overhead costs. In August 2017, the Company was approved to have cannabis in the building, and operate on December 29, 2017 just in time for *Adult-Use* legalization to take effect on January 1, 2018.

Weldon is the management company for Hollister Holistics 1 and Hollister Holistics 2 (collectively "Hollister Cannabis Company"), which both operate in the legal cannabis industry in California. Hollister Cannabis Company manufactures hash, tinctures, hash infused products, crumble infused products, pre-rolls, and other cannabis products under their brands HashBones, Purity Petibles, Hollister Cannabis Co., and as contract manufacturing white label products for other companies.

Currently, the most widely distributed product manufactured at Hollister Cannabis Company is the HashBone which is a 25% hash 75% flower pre-roll which is made in small batches with only premium flower and artisanal bubble hash. Hollister Cannabis Company Bubble Hash is made with purified water and ice in hash wash machines. It is dried in state of the art freeze dryers and strained and grammed in concentrate jars. There are several white label products manufactured at Hollister Cannabis Company including crumble infused pre-rolls, 1/8th and grammed flower, and pre-rolls. The Company uses an automated process that fills vape cartridges, capsules, tincture bottles and more. There are potential white label projects for this equipment. Most products are packaged, labeled, and prepared for distribution prior to leaving Hollister Cannabis Company. The Company employs an extremely efficient Auto Labe labeling machine for any round vessel, and a blister pack machine.

The Hollister Facility will house several projects that are currently under development including but not limited to automated pre-roll manufacturing, NanoPure, nano emulsified cannabis concentrate which will be sold both wholesale as an ingredient for other companies and power products for Hollister Cannabis Company and an extraction lab for Venom Extracts to commence operations in the state of

Hollister Biosciences Inc.

For the three and six months ended June 30, 2021 and 2020

Management's Discussion & Analysis

Expressed in United States Dollars

California. The first product to be launched is a fast acting sublingual spray. Beverages, edibles, and capsules will soon be produced. Hollister, through its wholly-owned subsidiary, Venom Extracts, operates a two storey, 11,000 square foot indoor cannabis facility located at 2046 W Ironwood Dr, Phoenix Arizona 85021 (the "Phoenix Facility"). The Phoenix Facility meets all security requirements under applicable laws and the Company uses this space for butane, propane and ethanol extraction and packaging in its manufacturing process for the production of cannabis concentrate products.

The Company uses the Hollister Facility and the Phoenix Facility for the production and downstream processing of cannabis products using plant materials purchased from the licensed marketplace. Some products are unprocessed (e.g. dried flowers), while others are processed (e.g. oil derived from the cannabis leaves).

The Company offers products in the medicinal and recreational spaces, including products in the categories of, distillates, cannabis concentrates, prepackaged flower, pre-roll, infused pre-roll, bubble hash, tinctures, beverages, edibles and pet products.

Hollister Cannabis Company is licensed by the city of Hollister and the State of California for Manufacturing and Distribution. The Company currently uses Nabis as its primary distributor in California and continues to evaluate additional or alternative distribution lines in California.

Venom Extracts is one of Arizona's premier extract brands and one of the state's largest producers of award-winning medical cannabis distillate and related products. With an experienced management team and focus on quality, Venom Extracts prides itself as a differentiated extraction company by producing legal Marijuana products at a price point that allows retailers the potential to generate higher margins.

The Company's expansion strategy is centered on entering new markets/states that are approved for medical cannabis use and/or approved or have a reasonable expectation to be approved for recreational use in the near future. During Q1 2021, the Company expanded its production capacity in Arizona to accommodate Adult Use. The Company expects its California brands to be available in the Arizona market by the end of 2021. Another key initiative for the Company in 2021 and 2022 will be greenfield development to build redundancy into the Company's supply chain of raw material, lower input costs and enhance profit margins.

In March 2020, the World Health Organization declared coronavirus COVID-19 a global pandemic. This contagious disease outbreak, which has continued to spread, and any related adverse public health developments, has adversely affected workforces, economies, and financial markets globally, potentially leading to an economic downturn. It is not possible for the Company to predict the duration or magnitude of the adverse results of the outbreak and its effects on the Company's business or results of operations at this time. COVID-19 has created a new set of challenges for Hollister and we have risen to that challenge. All of our employees have been able to continue to stay working in California during this time as Hollister was deemed an essential service. We have a full COVID-19 sanitization protocols in place to keep our employees safe. When the COVID-19 shutdowns started to happen Hollister jumped into action by manufacturing hand sanitizer to donate to the city, county and the local community. Hollister was awarded a certificate of appreciation from San Benito County for donating the hand sanitizer.

Hollister has been experiencing some delays in product packaging and delivery of raw materials that have extended our normal turnaround times to manufacture products for distribution. The Company foresees further supply constraints that may cause delays in the two to four week range, and is working to mitigate these delays. In the meantime, COVID-19 has accelerated the direct to consumer delivery plan, the brand is called Dreamy Delivery and the first delivery hub was launched during Q4 2020 with statewide service expected by the end of 2021. Hollister has completed the design phase for the eventual buildout of its Venom brand in the Hollister Facility however the Company will initially use an asset light approach to validate the Venom brand in the California marketplace. COVID-19 has also delayed the launching of initial products for AlphaMind Brands Inc. Tommy Chongs's Full Spectrum Elixir is now being distributed into California dispensaries by our distribution partner Nabis.

The Company's wholly owned subsidiary Hollister Holistics 2 ("HH2") applied for a non-storefront delivery license in the city of Hollister. On September 21, 2020 the City Council of Hollister unanimously approved HH2's application for a delivery license in the city of Hollister. The Company, through Hollister Holistics 2, was also approved for a similar licence for the state of California on January 12, 2021.

The Company has also opened a smaller depot in Oakland, CA and Sacramento, CA to service the Bay Area and the greater Sacramento area in California. The www.DreamyDelivery.com website for delivery has been launched and is currently accepting orders in the Bay Area of California, Sacramento and Hollister California.

Acquisition of AlphaMind Brands Inc.

On April 30, 2020, the Company closed its acquisition of AlphaMind Brands Inc (AlphaMind"), a Canada and US based growth stage company, which is developing certified legal mushroom based natural health products (the "AlphaMind Acquisition").

Hollister Biosciences Inc.

For the three and six months ended June 30, 2021 and 2020

Management's Discussion & Analysis

Expressed in United States Dollars

Pursuant to the terms of the AlphaMind Acquisition, the Company has acquired AlphaMind for consideration of \$517,613 which was satisfied by the issuance of 4,200,000 Hollister common shares at a fair value of CAD\$0.12 per share pro rata to the shareholders of AlphaMind and a commitment to issue an additional 1,800,000 common shares at a fair value of CAD\$0.12 per share to certain former shareholders of AlphaMind on the earlier of (i) AlphaMind's first production run or its first sales of product, or (ii) December 31, 2021.

AlphaMind continues to discover, develop and commercialize products using non-psychoactive mushroom blends using certified organic mushrooms growth in North America.

OVERALL PERFORMANCE

Management reviews, on a regular basis, the Company's accounting policies, assumptions, estimates and judgment in order to ensure that our consolidated financial statements are presented fairly and in accordance with IFRS.

For information regarding the Company's total assets and liabilities, refer to "Liquidity and Capital Resources" below.

SELECTED FINANCIAL INFORMATION - RESULTS OF OPERATIONS

For the three and six months ended June 30, 2021 and 2020:

	Q2 2021	Q2 2020	YTD 2021	YTD 2020
	\$	\$	\$	\$
Gross revenue	17,585,077	8,476,202	40,678,283	9,425,100
Gross profit	4,326,396	1,511,586	7,927,800	1,226,717
Operating expenses	(1,809,835)	(1,204,182)	(2,995,213)	(2,997,079)
Net income (loss) and comprehensive income (loss)	1,596,699	305,377	3,583,501	(1,848,102)
Total assets	24,379,009	22,708,931	24,379,009	22,708,931
Current liabilities	5,743,878	4,262,542	5,743,878	4,262,542

Review of consolidated financial information for Q2 2021 compared to Q2 2020

Gross revenue during the three months ended June 30, 2021, increased by \$9,108,875 or 107% compared to the prior year period, as the Company increased sales of existing products (pre-rolls and vape cartridges) and realized the revenues from Venom Extracts from the date of acquisition.

The composition of revenue for the three months ended June 30, 2021, included the following:

- \$15,262,990 – concentrates
- \$65,963 – hash bone (as described in "Corporate Outlook" above)
- \$152,137 – pre-rolls
- \$1,629,105 – vape cartridges
- \$4,874 – contract manufacturing services
- \$470,008 – other product sales

Comparatively, the composition of revenue during the three months ended June 30, 2020, was substantially comprised of sales of concentrates, hash bone, contract manufacturing services and discounts and allowances which totaled \$8,424,200, \$298,407, \$80,536 and a reduction of revenue by \$326,941, respectively.

Gross profit was \$4,326,396 for the three months ended June 30, 2021, compared to gross profit of \$1,511,586 for the prior year period. This change is primarily driven by increased sales in Hollister Cannabis Company and sales recognized from Venom Extracts, which was acquired on March 24, 2020. Gross profit for the current year period was also impacted by increases in most other cost components of inventory.

The portion of cost of sales that relates specifically to inventory (product, labour, testing, and supplies) amounted to \$11,968,177 during the three months ended June 30, 2021 (2020 - \$7,524,195), or 68% (2020 - 89%) of revenue. Key drivers in percentage fluctuations of cost of sales relative to revenue are fluctuating market prices of biomass inputs (product), as well as the addition of new production employees during the quarter.

Hollister Biosciences Inc.

For the three and six months ended June 30, 2021 and 2020

Management's Discussion & Analysis

Expressed in United States Dollars

Operating expenses during the three months ended June 30, 2021 were \$1,809,835, compared to \$1,204,182 during the prior year period. The increase is primarily driven by the growth of the Company, the continual evolution of the Company's activities and the expansion of sales efforts including increasing its sales mix and customer acquisition efforts. The most significant changes in operating expenses and other expenses were as follows:

- Administrative expense increased to \$268,494 during Q2 2021 from \$182,362 during Q2 2020 as a result of the Company's increased operations.
- Depreciation increased to \$327,081 during Q2 2021 from \$51,954 during Q2 2020 as a result of the Company's acquisition of Venom Extracts on March 24, 2020 which has a production facility that is required to be depreciated in accordance with IFRS.
- Marketing expenses decreased to \$107,636 during Q2 2021 from \$378,730 during Q2 2020 as a result of the Company's cost cutting initiatives.
- Share-based compensation increased to \$240,739 during Q2 2021 from \$nil during Q2 2020 as the Company issued stock options to employees during Q2 2021 and none were issued during Q2 2020.
- Salaries and wages increased to \$502,857 during Q2 2021 from \$200,265 during Q2 2020 as a result of the Company's growth and increased operations.

Review of consolidated financial information for YTD 2021 compared to YTD 2020

Gross revenue during the six months ended June 30, 2021, increased by \$31,253,183 or 332% compared to the prior year period, as the Company increased sales of existing products (pre-rolls and vape cartridges) and realized the revenues from Venom Extracts from the date of acquisition to the end of the quarter.

The composition of revenue for the six months ended June 30, 2021, included the following:

- \$34,616,434 – concentrates
- \$140,883 – hash bone (as described in "Corporate Outlook" above)
- \$265,338 – pre-rolls
- \$5,071,805 – vape cartridges
- \$4,874 – contract manufacturing services
- \$578,949 – other product sales

Comparatively, the composition of revenue during the six months ended June 30, 2020, was substantially comprised of sales of concentrates, hash bone, contract manufacturing services and discounts and allowances which totaled \$9,117,075, \$457,010, \$167,383 and a reduction of revenue by \$316,368, respectively.

Gross profit was \$7,927,800 for the six months ended June 30, 2021, compared to gross profit of \$1,226,717 for the prior year period. This change is primarily driven by increased sales of Hollister Cannabis Company and sales recognized from Venom Extracts, which was acquired on March 24, 2020. Gross profit for the current year period was also impacted by increases in cost components of inventory.

The portion of cost of sales that related specifically to inventory (product, labour, testing, and supplies) amounted to \$31,459,979 during the six months ended June 30, 2021 (2020 - \$7,874,174), or 77% (2020 - 84%) of revenue. Key drivers in percentage fluctuations of cost of sales relative to revenue are fluctuating market prices of biomass inputs (product), as well as the addition of new production employees during the quarter and the acquisition of Venom Extracts.

Operating expenses during the six months ended June 30, 2021 were \$2,995,213, compared to \$2,997,079 during the prior year period. The decrease is primarily driven by the prior year transaction costs as part of the Company's reverse acquisition to the CSE. Offsetting these cost reductions were increases in many of the other expense categories as part of the continual evolution of the Company's activities and expansion of sales efforts including increasing its sales mix and customer acquisition efforts. The most significant changes in operating expenses and other expenses were as follows:

- Administrative expense increased to \$462,563 during YTD 2021 from \$275,526 during YTD 2020 as a result of the Company's acquisition of Venom Extracts on March 24, 2020, which have various administrative costs.
- Depreciation increased to \$631,122 during YTD 2021 from \$129,053 during YTD 2020 as a result of the Company's acquisition of Venom Extracts on March 24, 2020 which has a production facility that is required to be depreciated in accordance with IFRS.
- Marketing expenses decreased to \$267,829 during YTD 2021 from \$849,862 during YTD 2020 as a result of the Company's cost cutting initiatives.
- Professional fees and consulting increased to \$466,938 during YTD 2021 from \$374,111 during YTD 2020 as a result of the Company's acquisition of Venom Extracts on March 24, 2020 and additional costs associated with the Company's continued growth.
- Share-based compensation increased to \$240,739 during YTD 2021 from \$nil during YTD 2020 as the Company issued stock options to employees during YTD 2021 and none were issued during YTD 2020.
- Salaries and wages increased to \$702,994 during YTD 2021 from \$262,764 during YTD 2020 as a result of the Company's acquisition of Venom Extracts on March 24, 2020, which has various full and part-time staff as part of its operation.
- Transaction costs decreased to \$nil during YTD 2021 from \$828,100 during YTD 2020 as a result of the Company's acquisition of Venom Extracts on March 24, 2020.

Hollister Biosciences Inc.

For the three and six months ended June 30, 2021 and 2020

Management's Discussion & Analysis

Expressed in United States Dollars

SUMMARY OF QUARTERLY RESULTS

	Revenue	Net income (loss) and comprehensive income (loss)	Income (loss) per share
	\$	\$	\$
June 30, 2021	17,585,077	1,596,699	0.01
March 31, 2021	23,093,206	1,986,802	0.01
December 31, 2020	11,710,491	(459,860)	(0.00)
September 30, 2020	9,489,911	(649,095)	(0.00)
June 30, 2020	8,476,202	305,377	0.00
March 31, 2020	951,761	(2,153,479)	(0.01)
December 31, 2019	347,362	(1,328,057)	(0.07)
September 30, 2019	236,603	(362,450)	(0.02)

Quarter to quarter fluctuations in revenue have been driven by fluctuations in the normal course of business, the Company's overall growth efforts and significant customer acquisitions in recent periods. Moreover, the Company's sales mix has expanded since the beginning of fiscal 2019, which is driving an upward trend in quarter-by-quarter revenue.

During the period ended March 31, 2020, the Company acquired Venom Extracts resulting in the recognition of a one-time non-cash transaction cost of \$828,100. Commencing the three months ended June 30, 2020, the Company realized increased sales of existing products (pre-rolls and vape cartridges) and the revenues from Venom Extracts from the date of acquisition.

LIQUIDITY AND CAPITAL RESOURCES**Capital Management**

The Company manages its capital structure and makes adjustments to it, based on the funds available to the Company, in order to maintain operations. The Board of Directors, which comprises of members of management, does not establish quantitative return on capital criteria, but rather relies on their expertise to sustain future development of the business. The Company defines capital that it manages as shareholders' equity. The Company has historically relied on financing from the issuance of Units, other arm's length financing arrangements, and the contributions of its officers to fund its activities. Management reviews its capital management approach on an on-going basis and believes that this approach, given the relative size of the Company, is reasonable.

The Company is not currently subject to externally imposed capital requirements. There were no changes in the Company's approach to capital management during the six months ended June 30, 2021.

Hollister Biosciences Inc.

For the three and six months ended June 30, 2021 and 2020

Management's Discussion & Analysis

Expressed in United States Dollars

Liquidity and Financial Condition

As at June 30, 2021 and December 31, 2020:

	June 30, 2021	December 31, 2020
	\$	\$
Cash	6,983,959	1,061,950
Receivables	4,299,414	2,849,775
Prepaid expenses	68,392	82,088
Inventory	4,241,699	2,203,133
Current portion of lease receivable	299,717	157,439
Current assets	15,893,181	6,354,385
Deposits	59,380	83,380
Property and equipment	2,797,963	3,152,638
Intangible assets	1,812,500	2,137,500
Lease receivable	1,595,357	879,484
Goodwill	2,220,628	2,220,628
Current liabilities	5,743,878	5,720,938
Non-current liabilities	3,460,037	4,036,325
Working capital	10,149,303	633,447
Shareholders' equity	15,175,094	5,070,752

The Company's current assets increased by \$9,696,235 in major part due to an increase in cash from financing, receivables and inventory. The Company had a positive working capital resulting from the significant increase in cash from proceeds on the issuance of common shares, partially offset by current liabilities characterized by minimal increases in accounts payable and accrued liabilities.

The Company is in a deficit position due to the historic losses incurred during prior periods. Details of which are further discussed in note 2 to the Company's interim financial statements. Fluctuations in cash are discussed below under "Cash flows".

Cash flows

	Q2 2021	Q2 2020	YTD 2021	YTD 2020
	\$	\$	\$	\$
Net cash provided by (used in) operating activities	147,361	79,699	1,044,641	(565,986)
Net cash (used in) provided by investing activities	(86,386)	(174,841)	(917,165)	600,137
Net cash provided by (used in) financing activities	291,474	(177,505)	5,778,722	(406,465)
Impact of exchange rate changes on cash	(282,355)	42,322	15,811	(33,390)
Net increase (decrease) in cash	70,094	(230,325)	5,922,009	(405,704)
Cash, beginning of period	6,913,865	1,280,770	1,061,950	1,456,149
Cash, end of period	6,983,959	1,050,445	6,983,959	1,050,445

Q2 2021 versus Q2 2020

- Cash provided by operating activities of \$147,361 (Q2 2020 - \$79,699) were the result of net cash inflows from revenue activity, partially offset by cash spent on inventory, deposits and paying down accounts payable. During the prior year comparable period, the Company generated net cash outflows, which were fully offset by the Company conserving cash through utilizing available credit on accounts payable and accrued liabilities causing such balance to increase. Similarly, a significant portion of management fees were accrued and unpaid during the period to conserve cash.
- Cash used in investing activities of \$86,386 (Q2 2020 - \$174,841) comprised the purchase of equipment.
- Cash provided by financing activities totaled \$291,474 (used in Q2 2020 - \$177,505) which was primarily driven by proceeds from exercises of warrants, offset by payments of obligations under lease.

Hollister Biosciences Inc.

For the three and six months ended June 30, 2021 and 2020

Management's Discussion & Analysis

Expressed in United States Dollars

YTD 2021 versus YTD 2020

- Cash provided by operating activities of \$1,044,641 (used in YTD 2020 - \$565,986) were the result of net cash inflows from revenue activity, partially offset by cash spent on inventory and paying down accounts payable. During the prior year comparable period, the Company generated net cash outflows from cash spent on inventory, deposits and prepaid expenses.
- Cash used in investing activities totaling \$917,165 (provided during YTD 2020 - \$600,137), comprised the purchase of equipment, and payments of deferred compensation for the acquisition of Venom Extracts. During the prior year comparable period, the Company generated net cash inflows from the cash acquired from the acquisition of Venom Extracts, offset by a deferred compensation payable arising from the acquisition and purchases of equipment.
- Cash provided by financing activities totaled \$5,778,722 (used in YTD 2020 - \$406,465) were the result of a private placement financing of special warrants and proceeds from option and warrant exercises, partially offset by repayments of lease liabilities which includes payments on the Company's facility lease, as well as repayments on long-term debt and promissory notes. During the prior year comparable period, the Company generated net cash outflows due to repayments of lease liabilities.

USE OF NON-IFRS FINANCIAL MEASURES

This press release includes certain non-IFRS financial measures as defined by the SEC. Reconciliations of these non-IFRS financial measures to the most directly comparable financial measure calculated and presented in accordance with IFRS are included below. This information should be considered as supplemental in nature and not as a substitute for, or superior to, any measure of performance prepared in accordance with IFRS. Our management uses adjusted EBITDA to evaluate our operating performance and trends and make planning decisions. Our management believes adjusted EBITDA helps identify underlying trends in our business that could otherwise be masked by the effect of the items that we exclude. Accordingly, we believe that adjusted EBITDA provides useful information to investors and others in understanding and evaluating our operating results, enhancing the overall understanding of our past performance and future prospects, and allowing for greater transparency with respect to key financial metrics used by our management in its financial and operational decision-making.

The table below reconciles net income (loss) and comprehensive income (loss) to Adjusted EBITDA (LOSS) for the three and six months ended June 30, 2021 and 2020:

	Three months ended June 30,		Six months ended June 30,	
	2021	2020	2021	2020
	\$	\$	\$	\$
Net income (loss) and comprehensive income (loss)	1,596,699	305,377	3,583,501	(1,848,102)
Add (deduct) impact of:				
Accretion	-	3,151	-	6,301
Depreciation	327,081	51,954	631,122	129,053
Finance costs	108,423	110,179	209,605	219,861
Foreign exchange gain	-	-	(28,296)	-
Interest expense	2,500	37,500	20,014	50,000
Share-based compensation	240,739	-	240,739	-
Transaction costs	-	-	-	828,100
Interest income	(40,478)	-	(66,088)	-
Gain on sublease	(262,015)	-	(262,015)	-
Income tax expense	1,013,000	-	1,821,000	-
Deferred income tax recovery	(73,000)	-	(128,000)	-
Foreign currency translation adjustment	282,355	2,027	(15,811)	77,740
Adjusted EBITDA (LOSS)	3,195,304	510,188	6,005,771	(537,047)

OUTSTANDING SHARE DATA

Summary of outstanding share data as of date of this MD&A:

Authorized: Unlimited number of common shares without par value.

Issued and outstanding: 269,878,252 common shares

Stock options: 18,971,666

Warrants: 22,939,862

Hollister Biosciences Inc.

For the three and six months ended June 30, 2021 and 2020

Management's Discussion & Analysis

Expressed in United States Dollars

FINANCIAL INSTRUMENTS AND RISK MANAGEMENT

Fair value of financial instruments

IFRS 13 establishes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities and the lowest priority to unobservable inputs. The three levels of the fair value hierarchy are as follows:

- Level 1 – Unadjusted quoted prices in active markets for identical assets or liabilities;
- Level 2 – Inputs other than quoted prices that are observable for the asset or liability either directly or indirectly; and
- Level 3 – Inputs that are not based on observable market data.

The carrying values of cash, receivables, accounts payable and accrued liabilities, and accounts payable to related parties approximate their respective fair values due to the short-term nature of these instruments. Long-term debt and lease obligations also approximate their respective fair values as these instruments are either discounted using market rates of interest or bear a market rate of interest.

The Company's potential sources of cash flow in the upcoming year will be from possible equity or debt financings.

Economic dependence

During the six months ended June 30, 2021, the Company derived 50% of its revenues from six customers (2020 - 31% from four customers) with the remaining sales being made to a variety of customers.

OFF-BALANCE SHEET ARRANGEMENTS

The Company has no off-balance sheet arrangements as at June 30, 2021 and December 31, 2020, and as at the date hereof.

RELATED PARTY TRANSACTIONS

Key management personnel are those persons having the authority and responsibility for planning, directing and controlling the activities of the Company, directly or indirectly. Key management personnel include officers and directors of the Company. The remuneration of the Company's key management personnel during the three and six months ended June 30, 2021 and 2020 are as follows:

	Three months ended June 30,		Six months ended June 30,	
	2021	2020	2021	2020
	\$	\$	\$	\$
Salaries and wages	11,038	20,833	82,913	83,333
Professional and consulting fees	58,122	19,518	94,653	39,036
	69,160	40,351	177,566	122,369

As at June 30, 2021, accounts payable to Amasa Lacy (a Vice President, Production and director of the Company) totalled \$44,083 (December 31, 2020 - \$59,083) and accounts payable to Carl Saling (CEO and director of the Company) totalled \$63,477 (December 31, 2020 - \$63,612). These amounts are unsecured, non-interest bearing and are due on demand.

USE OF ESTIMATES AND JUDGEMENTS

The preparation of financial statements requires management to make judgments, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets and liabilities, revenues and expenses. Management continually evaluates these judgments, estimates and assumptions based on experience and other factors, including expectations of future events that are believed to be reasonable under the circumstances. Actual results may differ from these estimates and judgments which may cause a material adjustment to the carrying amounts of assets and liabilities. Details of the areas which require management to make critical estimates and judgments are disclosed in note 3 of the Company's audited consolidated financial statements for the years ended December 31, 2020 and 2019.

ACCOUNTING STANDARDS AND INTERPRETATIONS

The interim financial statements have been prepared in accordance with IFRS as issued by the IASB, effective as of June 30, 2021. The Company's significant accounting policies are described in note 3 of the Company's audited consolidated financial statements for the years ended December 31, 2020 and 2019.

Hollister Biosciences Inc.

For the three and six months ended June 30, 2021 and 2020

Management's Discussion & Analysis

Expressed in United States Dollars

LEGAL AND REGULATORY MATTERS

For a detailed listing of the legal and regulatory considerations impacting the Company, please refer to the Company's MD&A for the year ended December 31, 2020.

RISKS AND UNCERTAINTIES

For a detailed listing of the risk factors faced by the Company, please refer to the Company's MD&A for the year ended December 31, 2020.

ADDITIONAL RISK DISCLOSURE FOR ISSUERS WITH U.S. CANNABIS OPERATIONS

Unfavorable Publicity or Consumer Perception

Proposed management of the Company believes the recreational cannabis industry is highly dependent upon consumer perception regarding the safety, efficacy and quality of the recreational cannabis produced. Consumer perception of the Company's proposed products may be significantly influenced by scientific research or findings, regulatory investigations, litigation, media attention and other publicity regarding the consumption of recreational cannabis products. There can be no assurance that future scientific research, findings, regulatory proceedings, litigation, media attention or other research findings or publicity will be favorable to the recreational cannabis market or any particular product, or consistent with earlier publicity. Future research reports, findings, regulatory proceedings, litigation, media attention or other publicity that are perceived as less favorable than, or that question, earlier research reports, findings or publicity could have a material adverse effect on the demand for the Company's proposed products and the business, results of operations, financial condition and cash flows of the Company. The Company's dependence upon consumer perceptions means that adverse scientific research reports, findings, regulatory proceedings, litigation, media attention or other publicity, whether or not accurate or with merit, could have a material adverse effect on the Company, the demand for the Company's proposed products, and the business, results of operations, financial condition and cash flows of the Company. Further, adverse publicity reports or other media attention regarding the safety, efficacy and quality of recreational cannabis in general, or the Company's proposed products specifically, or associating the consumption of recreational cannabis with illness or other negative effects or events, could have such a material adverse effect. Such adverse publicity reports or other media attention could arise even if the adverse effects associated with such products resulted from consumers' failure to consume such products appropriately or as directed.

ADDITIONAL RISK DISCLOSURE FOR ALPHAMIND BRANDS

AlphaMind's prospects depend on the success of its products/compounds which are not yet in development

AlphaMind currently has no products/compounds that have been approved by Health Canada or any similar regulatory authority. To obtain regulatory approvals for its product/compound candidates being developed and to achieve commercial success, clinical trials may be required to demonstrate that the product/compound candidates are safe for human use and that they demonstrate efficacy to varying degrees of certainty depending on the product. Many product/compound candidates never reach the stage of clinical testing and even those that do have only a small chance of successfully completing clinical development and gaining regulatory approval. Product/compound candidates may fail for a number of reasons, including, but not limited to, being unsafe for human use or due to the failure to provide therapeutic benefits equal to or better than the standard of treatment at the time of testing. Unsatisfactory results obtained from a particular study relating to a research and development program may cause AlphaMind or its collaborators to abandon commitments to that program. Positive results of early preclinical research may not be indicative of the results that will be obtained in later stages of preclinical or clinical research. Similarly, positive results from early-stage clinical trials may not be indicative of favorable outcomes in later-stage clinical trials, and AlphaMind can make no assurance that any future studies, if undertaken, will yield favorable results.

The psychedelic industry and market are relatively new and this industry may not succeed in the long term.

There is no assurance that the industry and market will continue to exist and grow as currently estimated or anticipated or function and evolve in the manner consistent with management's expectations and assumptions. Any event or circumstance that adversely affects the psychedelic industry and market could have a material adverse effect on AlphaMind's business, financial conditions and results of operations. The psychedelic market will face specific marketing challenges given the products' status as a controlled substance which resulted in past and current public perception that the products have negative health and lifestyle effects and have the potential to cause physical and social harm due to psychoactive and potentially addictive effects.

AlphaMind expects to rely on contract manufacturers over whom it will have limited control. AlphaMind may rely on contract manufacturing organizations ("CMOs") for manufacturing, formulation, filling, packaging, storing and shipping of drug product in compliance with current Good Manufacturing Practices ("cGMP") regulations applicable to its products/compounds. Health Canada and the FDA and other equivalent regulatory bodies in other jurisdictions ensure the quality of drug products by carefully monitoring drug manufacturers' compliance with cGMP regulations.

